Related Experiment Videos
Elucidation of gene function using C-5 propyne antisense oligonucleotides
W M Flanagan1, L L Su, R W Wagner
1Gilead Sciences, Foster City, CA 94404, USA. michael_flanagan@gilead.com
Abstract:
Identification of human disease-causing genes continues to be an intense area of research. While cloning of genes may lead to diagnostic tests, development of a cure requires an understanding of the gene's function in both normal and diseased cells. Thus, there exists a need for a reproducible and simple method to elucidate gene function. We evaluate C-5 propyne pyrimidine modified phosphorothioate antisense oligonucleotides (ONs) targeted against two human cell cycle proteins that are aberrantly expressed in breast cancer: p34cdc2 kinase and cyclin B1. Dose-dependent, sequence-specific, and gene-specific inhibition of both proteins was achieved at nanomolar concentrations of ONs in normal and breast cancer cells. Precise binding of the antisense ONs to their target RNA was absolutely required for antisense activity. Four or six base-mismatched ONs eliminated antisense activity confirming the sequence specificity of the antisense ONs. Antisense inhibition of p34cdc2 kinase resulted in a significant accumulation of cells in the Gap2/mitosis phase of the cell cycle in normal cells, but caused little effect on cell cycle progression in breast cancer cells. These data demonstrate the potency, specificity, and utility of C-5 propyne modified antisense ONs as biological tools and illustrate the redundancy of cell cycle protein function that can occur in cancer cells.
Insights
Modified antisense oligonucleotides (ONs) effectively inhibit cell cycle genes in breast cancer cells. This demonstrates their utility for studying gene function and reveals potential cancer cell adaptability.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Understanding gene function is crucial for developing disease cures.
- Aberrant expression of cell cycle proteins like p34cdc2 kinase and cyclin B1 is common in breast cancer.
- A simple and reproducible method is needed to elucidate gene function.
Purpose of the Study:
- To evaluate the efficacy of C-5 propyne pyrimidine modified phosphorothioate antisense oligonucleotides (ONs) in inhibiting p34cdc2 kinase and cyclin B1.
- To assess the specificity and utility of these modified ONs as biological tools.
- To investigate the impact of inhibiting p34cdc2 kinase on cell cycle progression in normal and breast cancer cells.
Main Methods:
- Utilized C-5 propyne pyrimidine modified phosphorothioate antisense oligonucleotides (ONs) targeting p34cdc2 kinase and cyclin B1.
- Administered ONs to normal and breast cancer cells in dose-dependent and sequence-specific manner.
- Analyzed cell cycle progression using flow cytometry after ON treatment.
Main Results:
- Achieved dose-dependent, sequence-specific, and gene-specific inhibition of p34cdc2 kinase and cyclin B1 at nanomolar concentrations.
- Confirmed that precise RNA binding of ONs was essential for antisense activity; mismatches abolished it.
- Observed significant G2/M phase cell cycle arrest in normal cells upon p34cdc2 kinase inhibition, with minimal effect on breast cancer cells.
Conclusions:
- C-5 propyne modified antisense ONs are potent and specific biological tools for gene function studies.
- Breast cancer cells may exhibit functional redundancy in cell cycle protein pathways, contributing to resistance.
- These findings highlight the potential of antisense technology in cancer research and therapeutic development.